• No results found

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

N/A
N/A
Info
Downloaden
Protected

Academic year: 2021

Share "University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Download het nu ( 2 pagina )

Hele tekst

(1)

University of Groningen

Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory

bowel disease

Buurman, Dorien Joke

DOI:

10.33612/diss.98535663

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Buurman, D. J. (2019). Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.98535663

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen

Behorende bij het proefschrift

‘Complications and optimalisation of

Mesalazine and anti-TNF-alpha therapy

in inflammatory bowel disease’

door Dorien J. Buurman

1. Bij patiënten met colitis ulcerosa die een inflammatoire reactie vertonen na inname van mesalazine is rechallenge niet zinvol (dit proefschrift)

2. Patiënten met colitis ulcerosa die een inflammatoire respons op het

medicament mesalazine vertonen kunnen niet worden gedesensitiseerd met een driedaags desensitisatie-schema (dit proefschrift)

3. Er is een goede correlatie tussen de verschillende meetmethoden voor het meten van anti-TNF-alpha drug levels en antistoffen (dit proefschrift) 4. Er is geen cross-reactiviteit tussen antistoffen tegen Infliximab en

Adalimumab maar wel tussen infliximab originator en de infliximab biosimilar CT-P13 (Remsima, Inflectra) (dit proefschrift)

5. Selectieve dalspiegelmeting van infliximab is kosteneffectief

(dit proefschrift)

6. Met een pharmaco-genetisch paspoort kunnen een aantal bijwerkingen van medicamenten voorkomen worden

7. Mogelijk dat infliximab in de toekomst oraal wordt toegediend

(dit proefschrift)

8. De opleiding tot medisch specialist combineren met promotieonderzoek is uitdagend en verrijkend

9. Als je het niet meer trekt, moet je duwen (Pippi Langkous)

Referenties

Download het nu ( PDF - 2 pagina - 189.69 KB )

GERELATEERDE DOCUMENTEN

Golimumab bij Colitis Ulcerosa MDL

Golimumab wordt soms als enige middel tegen colitis ulcerosa gebruikt, maar kan ook worden gecombineerd met andere afweer.. onderdrukkende middelen (azathioprine/ 6-

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

is correlated with the HLA-DRB1*03 allele. The HLA-DQA1*05 signal could thus be driving the HLA-DRB1*03 association signal. This highlights the need for additional studies to

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

Our simulations also showed that for patients without ATI, it may be considered to dose every 12 weeks instead of every 8 weeks: at dose relative to 400 mg / 8 weeks, this is

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

Bioavailability, lag- and pulse time were evaluated to determine whether there is any difference between healthy volunteers and Crohn’s patients in the in vivo drug

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

Primary objective of the study is to investigate the efficacy oral IFX biosimilar CT- P13 in ColoPulse tablets to induce clinical remission based on CDAI score of < 150 at week

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase 1 open-label randomised controlled trial in patients with

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

Antistoffen gericht tegen TNF alpha (anti-TNF-alpha) zoals Infliximab en Adalimumab worden bij zowel de ziekte van Crohn als colitis ulcerosa gebruikt.. Tegen deze in de

University of Groningen Complications and optimalisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease Buurman, Dorien Joke

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With